{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:06:13Z","timestamp":1791216373398,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cefiderocol is a novel siderophore-conjugated cephalosporin with activity against antimicrobial-resistant Gram-negative bacteria. Despite increasing off-label use in critically ill neonates and children, data on its safety and effectiveness remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective case series of neonatal and pediatric patients (\u226418 years) who received off-label cefiderocol across 3 tertiary-care hospitals in Greece for suspected or documented infections due to multidrug-resistant Gram-negative bacteria. We also conducted a systematic review of pediatric cases published through June 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifteen patients [median age 65 months (range 4\u2013183)] received 21 cefiderocol courses. The systematic review identified 37 additional treatment courses (32 patients, 6 of them &lt;3 months of age), primarily for bloodstream infections (86%), pneumonia (24.3%) and febrile neutropenia (18.9%). Most patients had received multiple antibiotics before and concomitantly with cefiderocol for extensively resistant Gram-negative bacteria. Clinical response occurred in 16\/21 (76.2%) courses in the case series study and 22\/28 (78.6%) courses in the systematic review. Microbiologic clearance was observed in 7\/9 (78%) courses in the case series. Cefiderocol was well-tolerated without serious adverse events in all cases. Most isolates (14\/18, 78%) were susceptible to cefiderocol according to current breakpoints, with a single instance of resistance emergence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This is the largest pediatric cohort to date combining real-world and published cefiderocol cases, suggesting that cefiderocol is a safe, well-tolerated and potentially effective option for severe, difficult-to-treat antimicrobial-resistant Gram-negative infections in neonates and children. These results support cautious off-label use in critically ill patients, while underscoring the urgent need for further pediatric trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005134","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:00:37Z","timestamp":1767589237000},"page":"603-609","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Real-world Use of Cefiderocol in Neonatal and Pediatric Populations: A Multicenter Case Series and Systematic Review"],"prefix":"10.1097","volume":"45","author":[{"given":"Chrysanthi","family":"Mantsiou","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Pediatrics, Aristotle University School of Medicine and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8333-3318","authenticated-orcid":false,"given":"Argyro","family":"Ftergioti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Pediatrics, Aristotle University School of Medicine and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-0484","authenticated-orcid":false,"given":"Elif","family":"B\u00f6nc\u00fco\u011flu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Buca Seyfi Demirsoy Education and Research Hospital, Izmir Democracy University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Kiymet","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, \u00c7i\u011fli Education and Research Hospital, Izmir Bakir\u00e7ay University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki-Eleni","family":"Sfetsiori","sequence":"additional","affiliation":[{"name":"Oncology Department, Aglaia Kyriakou Children Hospital, Children\u2019s Oncology Unit \u201cMarianna V. Vardinoyannis-ELPIDA\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Syggelou","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Second Department of Pediatrics, Aglaia Kyriakou Children Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2775-3670","authenticated-orcid":false,"given":"Filippos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens and Aghia Sophia Children Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0187-6795","authenticated-orcid":false,"given":"Dimitrios","family":"Doganis","sequence":"additional","affiliation":[{"name":"Oncology Department, Aglaia Kyriakou Children Hospital, Children\u2019s Oncology Unit \u201cMarianna V. Vardinoyannis-ELPIDA\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2485-4409","authenticated-orcid":false,"given":"Maria","family":"Tsolia","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Second Department of Pediatrics, Aglaia Kyriakou Children Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-1118","authenticated-orcid":false,"given":"Athanasios","family":"Michos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens and Aghia Sophia Children Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-364X","authenticated-orcid":false,"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Pediatrics, Aristotle University School of Medicine and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-451X","authenticated-orcid":false,"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Pediatrics, Aristotle University School of Medicine and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"R1-20260609","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3390\/antibiotics12111626","article-title":"Increase in incidence rates and risk factors for multidrug resistant bacteria in septic children: a Nationwide Spanish Cohort Study (2013\u20132019).","volume":"12","author":"Slocker-Barrio","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R2-20260609","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli.","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"Suppl 1","key":"R3-20260609","doi-asserted-by":"crossref","first-page":"31","DOI":"10.37201\/req\/s01.07.2022","article-title":"Cefiderocol.","volume":"35","author":"Soriano","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"R4-20260609","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s15010-024-02404-9","article-title":"Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol.","volume":"53","author":"Trauth","year":"2024","journal-title":"Infection"},{"key":"R7-20260609","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/INF.0000000000004529","article-title":"Pharmacokinetics, safety and tolerability of single-dose or multiple-dose cefiderocol in hospitalized pediatric patients three months to less than eighteen years old with infections treated with standard-of-care antibiotics in the PEDI-CEFI phase 2 study.","volume":"44","author":"Bradley","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20260609","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00228-018-2458-9","article-title":"Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.","volume":"74","author":"Katsube","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-20260609","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1097\/INF.0000000000004247","article-title":"Off-label use of ceftazidime\/avibactam in neonatal intensive care unit: a real-life experience and literature review.","volume":"43","author":"Ftergioti","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R14-20260609","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0000000000002344","article-title":"Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant klebsiella pneumoniae in neonates and children <5 years of age.","volume":"38","author":"Iosifidis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20260609","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20260609","first-page":"180","article-title":"JBI Critical appraisal checklist for systematic reviews and research syntheses.","volume":"45","author":"Hilton","year":"2024","journal-title":"J Can Heal Libr Assoc"},{"key":"R17-20260609","first-page":"S330","article-title":"Prediction of cefiderocol pharmacokinetics and probability of target attainment in pediatric subjects for proposing dose regimens.","volume":"6","author":"Katsube","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R18-20260609","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"R19-20260609","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and achromobacter xylosoxidans infections.","volume":"73","author":"Warner","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R20-20260609","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12098-022-04468-7","article-title":"Cefiderocol as salvage therapy for carbapenem-resistant Klebsiella pneumoniae sepsis in an extremely preterm neonate.","volume":"90","author":"Bawankule","year":"2023","journal-title":"Indian J Pediatr"},{"key":"R21-20260609","doi-asserted-by":"crossref","first-page":"ofad174","DOI":"10.1093\/ofid\/ofad174","article-title":"Successful treatment of persistent Stenotrophomonas maltophilia bacteremia with cefiderocol in an infant.","volume":"10","author":"Hsu","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R22-20260609","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/INF.0000000000004051","article-title":"Successful use of cefiderocol to treat a multidrug-resistant Stenotrophomonas maltophilia ventilator-associated pneumonia in an extremely preterm neonate.","volume":"42","author":"Koirala","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20260609","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/antibiotics13010037","article-title":"The use of cefiderocol as salvage therapy in an infant receiving ECMO and continuous renal replacement therapy.","volume":"13","author":"Mercadante","year":"2024","journal-title":"Antibiotics"},{"key":"R24-20260609","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40121-022-00735-4","article-title":"Bloodstream infection due to a VIM-Metallo-\u03b2-lactamase-producing Klebsiella pneumoniae treated with cefiderocol in a preterm newborn.","volume":"12","author":"Monari","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R25-20260609","doi-asserted-by":"crossref","first-page":"116539","DOI":"10.1016\/j.diagmicrobio.2024.116539","article-title":"Cefiderocol as rescue therapy in a cancer immunosuppressed critically ill child: case description and literature review.","volume":"110","author":"A\u00f1\u00f3n-Hidalgo","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R26-20260609","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/INF.0000000000004347","article-title":"Use of cefiderocol in the management of children with infection or colonization with multi-drug resistant Gram-negative bacteria a retrospective, single-center case series.","volume":"43","author":"Schmid","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R27-20260609","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/cid\/ciad759","article-title":"Sequential treatment failure with aztreonam-ceftazidime-avibactam followed by cefiderocol due to preexisting and acquired mechanisms in a New Delhi Metallo-\u03b2-lactamase-producing Escherichia coli causing fatal bloodstream infection.","volume":"78","author":"Senchyna","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R28-20260609","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0000000000004150","article-title":"Cefiderocol red wine urine syndrome in pediatric patients: a multicenter case series.","volume":"43","author":"Shapiro","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20260609","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.phoj.2025.02.003","article-title":"Cefiderocol for severe bloodstream infection by multidrug-resistant Klebsiella pneumoniae in a pediatric patient with acute myeloid leukemia.","volume":"10","author":"De Leonardis","year":"2025","journal-title":"Pediatr Hematol Oncol J"},{"key":"R30-20260609","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/microorganisms13020330","article-title":"Use of cefiderocol in management of resistant Gram-negative infections in patients admitted to a burn center.","volume":"13","author":"Lane","year":"2025","journal-title":"Microorganisms"},{"key":"R31-20260609","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/jac\/dkad277","article-title":"Plasmatic and CSF concentrations of cefiderocol in an infant with extensively drug-resistant Pseudomonas aeruginosa meningoencephalitis.","volume":"78","author":"Funiciello","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"R32-20260609","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jgar.2021.04.025","article-title":"Compassionate use of cefiderocol for VIM metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma.","volume":"26","author":"Grasa","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"R33-20260609","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae in a pediatric patient.","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-20260609","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine).","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R35-20260609","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections.","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R36-20260609","doi-asserted-by":"crossref","first-page":"piaf004","DOI":"10.1093\/jpids\/piaf004","article-title":"Suggested dosing of select beta-lactam agents for the treatment of antimicrobial-resistant Gram-negative infections in children.","volume":"14","author":"Lockowitz","year":"2025","journal-title":"J. Pediatric Infect. Dis. Soc"},{"key":"R37-20260609","doi-asserted-by":"crossref","first-page":"104794","DOI":"10.1016\/j.idnow.2023.104794","article-title":"Treatment of resistant Gram-negative bacilli in children.","volume":"53","author":"Cohen","year":"2023","journal-title":"Infect Dis Now"},{"key":"R38-20260609","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/ciaf071","article-title":"The effectiveness of newer beta-lactams for the treatment of antimicrobial-resistant Gram-negative meningitis.","volume":"80","author":"Hsu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R39-20260609","first-page":"819","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis with sulbactam-durlobactam.","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R42-20260609","first-page":"e00951","article-title":"Cefiderocol susceptibility testing and proposed clinical breakpoints for Enterobacterales and non-fermenting Gram-negative bacilli.","volume":"59","author":"Shortridge","year":"2021","journal-title":"J Clin Microbiol"},{"key":"R44-20260609","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in ICU patients.","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R45-20260609","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/mdr.2021.0180","article-title":"Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials.","volume":"28","author":"Nordmann","year":"2022","journal-title":"Microb Drug Resist"},{"key":"R46-20260609","doi-asserted-by":"crossref","first-page":"e0100923","DOI":"10.1128\/aac.01009-23","article-title":"The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.","volume":"68","author":"Teran","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"R47-20260609","doi-asserted-by":"crossref","first-page":"107321","DOI":"10.1016\/j.ijid.2024.107321","article-title":"Emergence of cefiderocol resistance during therapy in NDM-5\u2013producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations.","volume":"151","author":"Deroche","year":"2025","journal-title":"Int J Infect Dis"},{"key":"R48-20260609","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciab511","article-title":"Rapid development of cefiderocol resistance in carbapenem-resistant enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA.","volume":"74","author":"Klein","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R49-20260609","doi-asserted-by":"crossref","first-page":"e0029024","DOI":"10.1128\/aac.00290-24","article-title":"Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA.","volume":"68","author":"Huang","year":"2024","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:34:10Z","timestamp":1786037650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005134","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}